Pharma Industrial India Magazine - May-June 2024

PHARMA INDUSTRIALINDIA · MAY-JUN 24 27 ARTICLE demand for generic drugs is a significant growth driver. The Indian market’s ability to produce cost-effective generics ca- ters to a global demand, particularly in markets with stringent regulatory requirements. 2. Government Initiatives: Policies such as the Production Linked Incentive (PLI) schemes, adherence to Good Manufac- turing Practices (GMP), and the Promote Research in Pharma (PRIP) scheme support the sector, particularly in innovative research areas. 3. Provision of End-to-End Services: CDMOs continue to ex- pand their capabilities across all phases of development and commercialization, offering integrated services that cover the entire product lifecycle. 4. Technological Advancements: Adoption of advanced technologies and automation in drug discovery, formulation development, and manufacturing processes by Indian CRAMS providers has enhanced efficiency, reduced time-to-market, and improved quality. 5. Rising Exports: Growth in formulation export markets aids the CDMO segment in India, as many companies outsource their development and manufacturing activities to meet export demands. Market Barriers 1. Rising Competition Among Small Players: High compe- tition leads to price wars, lowering the bargaining power of smaller players. Smaller players often set market price refer- ences, intensifying price competition. 2. Infrastructure and Technological Limitations: Only a few players in the highly fragmented Indian CDMO industry pos- sess requisite drug research and development capabilities. Additionally, very few CDMOs have the necessary specialized teams and rapid prototyping capabilities. 3. Regulatory Challenges: CRAMS players must remain com- pliant with evolving regulations. They face various regulatory risks, such as government-imposed price ceilings. 4. Data Integrity Concerns: Concerns about the leakage of sensitive information to competitors remain a top concern for pharmaceutical companies. This reluctance to outsource re- search and manufacturing processes stems from data security concerns. Recent Developments Industry Consolidation Consolidation is gaining traction, with CDMOs providing com- prehensive end-to-end services at limited costs. Recent exam- ples of consolidation include: • Akums acquired one of Ankur Drugs’ production plants to boost production capacities of oral tablets and liquids. • Syngene International acquired a multi-modal biologic man- ufacturing facility from Stelis Biopharma for approximately USD 75 million. Expansion and Capacity Building CDMOs are making strategic investments in R&D and man- ufacturing facilities to enhance their capabilities. Examples include: • Aurigene Pharmaceutical Services, a CDMO unit of Dr. Reddy’s Laboratories, is setting up a production facility in Ge- nome Valley, Hyderabad, with an investment of USD 40 million. • Laurus Labs invested INR 1.6K crore during 2020–2021 and plans to invest INR 2.4K crore over 2023 and 2024 to expand its footprint across the country. Operational Enhancement Investments in operational capabilities to cater to emerging products with the latest technologies are on the rise. For exam- ple, nano technology for drug delivery is emerging as a new solution for cardiovascular disease treatment. AI in Drug Discovery and Development Large CROs are leveraging AI tools for virtual screening, lead optimization, prediction of drug-target interactions, and identi- fication of novel drug candidates. Examples include: • IQVIA’s AI-based NextGen smart trial platform to stream- line and track clinical trial communications. • Syngene International’s proprietary solutions for AI-based drug discovery programs. Emergence of Biopharma Outsourcing Indian CDMOs are expanding their capabilities to meet the growing demand from biopharma companies. Examples in- clude: • Enzene Biosciences , a biopharma company that offers inte- grated CDMO services for biologics, recently inaugurated an R&D facility in Pune. • Aragen is constructing a biologic manufacturing plant in Bengaluru, involving an investment of USD 30 million. Market Opportunities The biopharma sector presents significant opportunities due to the low tendency to switch biopharma clients. India is a key